tradingkey.logo
搜尋

Neogenomics Inc

NEO
添加自選
14.970USD
+0.380+2.60%
收盤 07/01, 16:00美東報價延遲15分鐘
1.94B總市值
虧損本益比TTM

Neogenomics Inc

14.970
+0.380+2.60%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.60%

5天

+16.05%

1月

+43.39%

6月

+27.30%

今年開始到現在

+27.30%

1年

+102.02%

關鍵數據
14.550今開
15.195最高
3.23M成交量
虧損本益比TTM
40.16本益比動
--股利TTM
2.49%換手率
14.590昨收
14.540最低
37.39M成交額
虧損本益比靜
2.34市淨率
0.00%股息率 TTM
-6.73%ROA
13.74052週最高
0.69量比
-78.73M淨利潤
129.65M總股本
-0.7722每股盈餘TTM
1.81Beta
-11.56%ROE
4.72052週最低
4.49%振幅
43.32%毛利率
1.94B總市值
12.71回報/風險
3.48%風險率

TradingKey Neogenomics Inc股票評分

單位: USD 更新時間: 2026-07-01

操作建議

Neogenomics Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療服務供應商行業排名30/75位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為15.06。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Neogenomics Inc評分

相關信息

行業排名
30 / 75
全市場排名
119 / 4564
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Neogenomics Inc亮點

亮點風險
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
業績高增長
公司營業收入穩步增長,連續3年增長22.93%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入727.33M美元
估值合理
公司最新PE估值-19.39,處於3年歷史合理位
機構加倉
最新機構持股156.61M股,環比增加4.58%
活躍度增加
近期活躍度增加,過去20天平均換手率0.79

分析師目標

基於 12 分析師
買入
評級
15.056
目標均價
+3.19%
漲幅空間

Neogenomics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Neogenomics Inc簡介

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
公司代碼NEO
公司Neogenomics Inc
CEOZook (Antony P)
網址https://neogenomics.com/

常見問題

Neogenomics Inc(NEO)的當前股價是多少?

Neogenomics Inc(NEO)的當前股價是 14.97。

Neogenomics Inc 的股票代碼是什麼?

Neogenomics Inc的股票代碼是NEO。

Neogenomics Inc股票的52週最高點是多少?

Neogenomics Inc股票的52週最高點是13.74。

Neogenomics Inc股票的52週最低點是多少?

Neogenomics Inc股票的52週最低點是4.72。

Neogenomics Inc的市值是多少?

Neogenomics Inc的市值是1.94B。

現在Neogenomics Inc(NEO)的股票是買入、持有還是賣出?

根據分析師評級,Neogenomics Inc(NEO)的總體評級為買入,目標價格為15.06。

Neogenomics Inc(NEO)股票的每股收益(EPS TTM)是多少

Neogenomics Inc(NEO)股票的每股收益(EPS TTM)是-0.84。